Welcome to the all-new Vetlearn

  • Vetlearn is getting a new home. Starting this fall,
    Vetlearn becomes part of the NAVC VetFolio family.

    You'll have access to the entire Compendium and
    Veterinary Technician archives and get to explore
    even more ways to learn and earn CE by becoming
    a VetFolio subscriber. Subscriber benefits:
  • Over 500 hours of interactive CE Videos
  • An engaging new Community for tough cases
    and networking
  • Three years of NAVC Conference Proceedings
  • All-new articles (CE and other topics) for the entire
    healthcare team

To access Vetlearn, you must first sign in or register.

registernow

  • Registration for new subscribers will open in August 2014!
  • Watch for additional exciting news coming soon!
Become a Member

Compendium September 2008 (Vol 30, No 9)

Veterinary Therapeutics Selected Abstract: Pharmacokinetics of Buprenorphine Following Intravenous and Oral Transmucosal Administration in Dogs

by Sara M. Cowan, DVM, Susan E. Bunch, DVM, PhD, DACVIM

    Abbo LA, Ko JCH, Maxwell LK, et al. Vet Ther 2008;9(2):83-93.

    Pharmacokinetic analysis of buprenorphine administered to six healthy dogs via the oral transmucosal (OTM) route at doses of 20 and 120 µg/kg was conducted using liquid chromatography"electrospray ionization"tandem mass spectroscopy (LC-ESI-MS/MS). Bioavailability was 38% ± 12% for the 20 µg/kg dose and 47% ± 16% for the 120 µg/kg dose. Maximum plasma concentrations were similar for buprenorphine doses of 20 µg/kg IV and 120 µg/kg OTM. Sedation and salivation were common side effects, but no bradycardia, apnea, or cardiorespiratory depressive effects were seen. When the two OTM dosing rates were normalized to dose, LC-ESI-MS/MS analysis of buprenorphine and its metabolites detected no significant difference (P > .05), indicating dose proportionality. The results of this study suggest that OTM buprenorphine may be an alternative for pain management in dogs.

    Click here to read the complete article from the Summer 2008 issue of Veterinary Therapeutics.

    This study was funded by the Purdue University School of Veterinary Medicine. Buprenorphine and metabolite determinations were partially funded by NIH grant RO1-DA10100.

    NEXT: Abstract Thoughts — Chronic Carpal Sprains in Doberman Pinschers

    didyouknow

    Did you know... The primary way to prevent serotonin syndrome is to avoid using (1) drug combinations that facilitate serotonin activity or (2) excessive amounts of a single serotonergic drug.Read More

    These Care Guides are written to help your clients understand common conditions. They are formatted to print and give to your clients for their information.

    Stay on top of all our latest content — sign up for the Vetlearn newsletters.
    • More
    Subscribe